Akari Therapeutics, Plc
AKTX
Rank in Stocks
#26933
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates... Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Share Price
$7.66
Last synced: 2026-11-09
Market Cap
$17.59M
Change (1 day)
3.93%
Change (1 year)
-67.62%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Akari Therapeutics, Plc (AKTX)
Category
Healthcare
EPS for Akari Therapeutics, Plc (AKTX)
EPS as of June 2026 TTM: $-1.60K
According to Akari Therapeutics, Plc's latest financial reports, its current EPS (TTM) is $-1.60K. At the end of 2025 the company had an EPS of $-20.80K, an increase over its 2024 EPS of $-132.80K.
EPS history for Akari Therapeutics, Plc from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.60K | -92.31% |
| 2025 | $-20.80K | -84.34% |
| 2024 | $-132.80K | -18.63% |
| 2023 | $-163.20K | -64.15% |
| 2022 | $-455.20K | -29.93% |
| 2021 | $-649.60K | -27.50% |
| 2020 | $-896.00K | -39.13% |
| 2019 | $-1.47M | -30.88% |
| 2018 | $-2.13M | -53.10% |
| 2017 | $-4.54M | 84.23% |
| 2016 | $-2.46M | -71.04% |
| 2015 | $-8.51M | 133.52% |
| 2014 | $-3.64M | 49.88% |
| 2013 | $-2.43M | 5,064,900.00% |
| 2012 | $-48.00 | -25.00% |
| 2011 | $-64.00 | 300.00% |
| 2010 | $-16.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -100.98% |
US
|
|
| $-7.07 | -99.56% |
US
|
|
| $-5.29 | -99.67% |
AU
|
|
| $12.88 | -100.81% |
BE
|
|
| $21.56 | -101.35% |
NL
|
Questions about Akari Therapeutics, Plc's earnings per share (EPS)
What is Akari Therapeutics, Plc's earnings per share (EPS)?
Akari Therapeutics, Plc's earnings per share (EPS) over the last twelve months is $-1.60K, as of Jun 2026.
What was Akari Therapeutics, Plc's earnings per share (EPS) in 2025?
In 2025, Akari Therapeutics, Plc's earnings per share (EPS) was $-20.80K, compared with $-132.80K in 2024.
How has Akari Therapeutics, Plc's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Akari Therapeutics, Plc's earnings per share (EPS) was highest in 2025 ($-20.80K) and lowest in 2020 ($-896.00K).
How does Akari Therapeutics, Plc's earnings per share (EPS) compare with similar companies?
Akari Therapeutics, Plc's earnings per share (EPS) ($-1.60K) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.